Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase -Facilitated Subcutaneous Infusion of Immunoglobulin G (FSCIG) in Patients Aged <18 Years with Primary Immunodeficiency Diseases (PID)

被引：0

作者：

Wasserman, Richard L. ^{[1
]}

Melamed, Isaac ^{[2
]}

Stein, Mark ^{[3
]}

Kobrynski, Lisa ^{[4
]}

Gupta, Sudhir ^{[5
]}

Engl, Werner ^{[6
]}

McCoy, Barbara ^{[7
]}

Leibl, Heinz ^{[6
]}

Yel, Leman ^{[7
]}

机构：

[1] Allergy Partners North Texas Res, Dallas, TX USA

[2] IMMUNOe Hlth Ctr, Centennial, CO USA

[3] Allergy Associates Palm Beaches, North Palm Beach, FL USA

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Univ Calif Irvine, Irvine, CA USA

[6] Shire, Vienna, Austria

[7] Shire, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2017年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

PO - 135

引用

页码：S53 / S54

页数：2

共 50 条

[1] Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G in Patients Aged ≥18 Years with Primary Immunodeficiency Diseases
Wasserman, Richard L.
Stein, Mark
Kobrynski, Lisa
Gupta, Sudhir
Grant, J. Andrew
Rubinstein, Arye
Engl, Werner
McCoy, Barbara
Leibl, Heinz
Yel, Leman
JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 : S53 - S53
[2] LONG-TERM SAFETY, EFFICACY, AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS INFUSION OF IMMUNOGLOBULIN G IN PATIENTS AGED ≥16 YEARS WITH PRIMARY IMMUNODEFICIENCIES
Wasserman, R. L.
Stein, M.
Kobrynski, L.
Gupta, S.
Grant, J.
Rubinstein, A.
Engl, W.
McCoy, B.
Leibl, H.
Yel, L.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A103 - A103
[3] Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
Wasserman, Richard L.
Melamed, Isaac
Stein, Mark R.
Engl, Werner
Sharkhawy, Marlies
Leibl, Heinz
Puck, Jennifer
Rubinstein, Arye
Kobrynski, Lisa
Gupta, Sudhir
Grant, Andrew J.
Ratnayake, Anoshie
Richmond, Wendell G.
Church, Joseph
Yel, Leman
Gelmont, David
JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (06) : 571 - 582
[4] Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
Richard L. Wasserman
Isaac Melamed
Mark R. Stein
Werner Engl
Marlies Sharkhawy
Heinz Leibl
Jennifer Puck
Arye Rubinstein
Lisa Kobrynski
Sudhir Gupta
Andrew J. Grant
Anoshie Ratnayake
Wendell G. Richmond
Joseph Church
Leman Yel
David Gelmont
Journal of Clinical Immunology, 2016, 36 : 571 - 582
[5] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PI)
Stein, M.
Wasserman, R. L.
Melamed, I.
Rubinstein, A.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
McCoy, B.
Gelmont, D.
Schiff, R. I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 135 - 136
[6] Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases
Wasserman, Richard L.
IMMUNOTHERAPY, 2017, 9 (12) : 1035 - 1050
[7] Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(®)) in immunodeficiency diseases: real-life data from a monocentric experience
Francesca Angelotti
Riccardo Capecchi
Daiana Giannini
Ornella Mazzarella
Valeria Rocchi
Paola Migliorini
Clinical and Experimental Medicine, 2020, 20 : 387 - 392
[8] LONG TERM SAFETY, EFFICACY AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IGG) (HYQVIA; IGHY) IN PATIENTS AGED ≥16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PID)
Wasserman, Richard L.
Stein, Mark
Kobrynski, Lisa
Gupta, Sudhir
Grant, J. Andrew
Rubinstein, Arye
Engl, Werner
McCoy, Barbara
Leibl, Heinz
Yel, Leman
JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 (03) : 312 - 312
[9] Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(R)) in immunodeficiency diseases: real-life data from a monocentric experience
Angelotti, Francesca
Capecchi, Riccardo
Giannini, Daiana
Mazzarella, Ornella
Rocchi, Valeria
Migliorini, Paola
CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 20 (03) : 387 - 392
[10] Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability
Wasserman, Richard L.
Melamed, Isaac
Kobrynski, Lisa
Puck, Jennifer
Gupta, Sudhir
Doralt, Jennifer
Sharkhawy, Marlies
Engl, Werner
Leibl, Heinz
Gelmont, David
Yel, Leman
IMMUNOTHERAPY, 2016, 8 (10) : 1175 - 1185

← 1 2 3 4 5 →

Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase -Facilitated Subcutaneous Infusion of Immunoglobulin G (FSCIG) in Patients Aged &lt;18 Years with Primary Immunodeficiency Diseases (PID)

Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase -Facilitated Subcutaneous Infusion of Immunoglobulin G (FSCIG) in Patients Aged <18 Years with Primary Immunodeficiency Diseases (PID)